Mogamulizumab-Associated Acute Myocarditis in a Patient With T-Cell Lymphoma.

Autor: Kwan JM; Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut, USA., Odanovic N; Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut, USA., Arbune A; Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut, USA., Higgins A; Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut, USA., Henry M; Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut, USA., Greif D; Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut, USA., Foss F; Section of Hematology, Yale University School of Medicine, New Haven, Connecticut, USA., Baldassarre LA; Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
Jazyk: angličtina
Zdroj: JACC. Case reports [JACC Case Rep] 2021 Jun 02; Vol. 3 (7), pp. 1018-1023. Date of Electronic Publication: 2021 Jun 02 (Print Publication: 2021).
DOI: 10.1016/j.jaccas.2021.04.001
Abstrakt: A 62-year-old woman with human T-lymphotropic virus type 1 cell lymphoma developed heart failure after mogamulizumab, an immunotherapy agent. Clinical presentation and cardiac magnetic resonance imaging were consistent with myocarditis, and a recurrence of heart failure occurred after rechallenge with the therapy. ( Level of Difficulty: Advanced. ).
Competing Interests: This work was supported by American Heart Association (grant #18CDA34110361; LAB, 2018). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
(© 2021 The Authors.)
Databáze: MEDLINE